EXHIBIT 99.01

The Private Securities Litigation Reform Act of 1995 (the "Act") provides a
"safe harbor" for "forward-looking statements" (as defined in the Act). The
Company's filings with the Securities and Exchange Commission, including its
Annual Report on Form 10-K, Annual Report to Shareholders, Forms 10-Q and Forms
8-K (along with any exhibits to such filings as well as any amendments to such
filings), press releases, other written or oral statements made by or on behalf
of the Company, may include or incorporate by reference forward-looking
statements which reflect the Company's current view (as of the date such
forward-looking statement is made) with respect to future events, prospects,
projections or financial performance. These forward-looking statements are
subject to various risks and uncertainties that could cause actual results to
differ materially from those contemplated, projected, anticipated or implied by
these forward-looking statements. These risks and uncertainties include, but are
not limited to:

- -    uncertainties relating to general economic, business and market conditions;

- -    the loss of one or more key customer or supplier relationships, such as
     pharmaceutical and medical/surgical manufacturers for which alternative
     supplies may not be available or easily replaceable, or changes to the
     terms of those relationships, such as changes in vendor supply chain
     management policies and the use of inventory management agreements;

- -    challenges associated with integrating our information systems with those
     of our customers and/or suppliers;

- -    potential liabilities associated with warranties of our information
     systems, and the malfunction or failure of our information systems or those
     of third parties with whom we do business, such as malfunctions or failures
     associated with date-related issues, incompatible software, improper coding
     and disruption to internet-related operations;

- -    the costs, difficulties, and uncertainties related to the integration of
     recently acquired businesses, including liabilities related to the
     operations of such businesses prior to their acquisition;

- -    changes to the presentation of financial results and position resulting
     from adoption of new accounting principles or upon the advice of our
     independent auditors or the staff of the SEC;

- -    changes in the distribution or outsourcing pattern for pharmaceutical and
     medical/surgical products and services, including an increase in direct
     distribution or a decrease in contract packaging by pharmaceutical
     manufacturers;

- -    changes in government regulations or our failure to comply with those
     regulations or other applicable laws;

- -    the costs and other effects of legal, regulatory and administrative
     proceedings;

- -    injury to person or property resulting from our manufacturing, packaging,
     repackaging, drug delivery system development and manufacturing,
     information systems, or pharmacy management services;

- -    competitive factors in our healthcare service businesses, including pricing
     pressures;

- -    unforeseen changes in our existing agency and distribution arrangements;

- -    the continued financial viability and success of our customers, suppliers,
     and franchisees;

- -    difficulties encountered by our competitors, whether or not we face the
     same or similar issues;

- -    technological developments and products offered by competitors;

- -    failure to retain or continue to attract senior management or key
     personnel;

- -    risks associated with international operations, including fluctuations in
     currency exchange ratios;

- -    costs associated with protecting our trade secrets and enforcing our
     patent, copyright and trademark rights, and successful challenges to the
     validity of our patents, copyrights or trademarks;

- -    difficulties or delays in the development, production, manufacturing, and
     marketing of new products and services, including difficulties or delays
     associated with obtaining requisite regulatory consents or approvals
     associated with those activities;

- -    strikes or other labor disruptions;

- -    labor, pension and employee benefit costs;

- -    pharmaceutical and medical/surgical manufacturers' pricing policies and
     overall drug price inflation;

- -    changes in hospital buying groups or hospital buying practices; and

- -    other factors described in the Company's Annual Report on Form 10-K or the
     documents we file with the SEC.

The words "believe", "expect", "anticipate", "project", and similar expressions
identify "forward-looking statements", which speak only as of the date the
statement was made. The Company undertakes no obligation (nor does it intend) to
publicly update or revise any forward-looking statements, whether as a result of
new information, future events or otherwise, except to the extent required under
applicable law.